Equillium (EQ) FCF Margin (2023 - 2024)
Equillium (EQ) posted quarterly FCF Margin of 75.2% for Q4 2024, down 1333.0% year-over-year from 6.1% in Q1 2024, and down 19.44% quarter-over-quarter from 62.96% in Q3 2024.
Powered by 
Analysis
Equillium (EQ) FCF Margin (2023 - 2024) Analysis & Trends
Equillium (EQ) has reported FCF Margin for 2 consecutive years, with 75.2% the latest figure, recorded in Q4 2024.
- In Q4 2024, FCF Margin fell 1333.0% year-over-year to 75.2%; the TTM figure through Sep 2025 stood at 521.86% (down 47502.0% YoY), while the FY2024 annual figure was 46.5%, up 1400.0% from the prior year.
- FCF Margin eased to 75.2% in Q4 2024 per EQ's latest filing, from 62.96% in the prior quarter.
- Across five years, FCF Margin topped out at 4.82% in Q2 2024 and bottomed at 90.04% in Q1 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -388.28% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 25.68% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 22.62% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 70.82% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -22.35% |
| 10 | Equillium | 249.33 Mn | 249.33 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2024 | -75.20% |
| Sep 30, 2024 | -62.96% |
| Jun 30, 2024 | 5.11% |
| Mar 31, 2024 | -82.88% |
| Dec 31, 2023 | -61.87% |
| Sep 30, 2023 | -21.52% |
| Jun 30, 2023 | -68.12% |
| Mar 31, 2023 | -90.04% |